Sol-Gel Technologies Ltd. announced on November 20, 2024, that it has received an extension from The Nasdaq Stock Market LLC. This extension grants the company an additional 180 calendar days to regain compliance with Nasdaq's minimum bid price requirement.
The extension provides Sol-Gel Technologies until May 19, 2025, to meet the requirement that its ordinary shares maintain a minimum bid price of $1.00 per share. This allows the company more time to address its share price and avoid potential delisting.
The company continues to conduct its Phase 3 clinical trial for SGT-610 and manage its approved dermatology products, TWYNEO and EPSOLAY. Maintaining its Nasdaq listing is important for investor visibility and access to capital markets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.